BioCentury | Sep 19, 2017
Distillery Therapeutics


INDICATION: Brain cancer In vitro and mouse studies identified a hedgehog pathway inhibitor that could help treat medulloblastoma. Optimization and testing in mouse fibroblast cell-based assays of a previously identified dihydrobenzooxazocin analog yielded a compound...
BioCentury | Jul 10, 2017
Distillery Therapeutics


INDICATION: Lung cancer Patient sample, cell culture and mouse studies suggest inhibiting GLI1 alone or in combination with PI3K could help treat squamous cell carcinoma (SCC) of the lung. In lung tissue samples from patients,...
BioCentury | May 31, 2017
Distillery Therapeutics


INDICATION: Myeloproliferative disorder Patient sample and mouse studies suggest inhibiting GLI1 -expressing cells could help treat myeloproliferative neoplasms (MPN). In patients with higher grades of MPN, bone marrow samples had a higher percentage of GLI1-expressing...
BioCentury | Feb 2, 2017
Translation in Brief

Repairing repair

A Stanford team has figured out one reason diabetics have impaired bone healing, and devised a method of boosting skeletal stem cell expansion to correct the complication. The January study in Science Translational Medicine builds...
BioCentury | Feb 1, 2017
Distillery Therapeutics


INDICATION: Bone repair Patient sample and mouse studies suggest IHH and SHH could help treat diabetes-associated bone fractures. In patients undergoing joint replacement, levels of IHH and GLI family zinc finger 1 (GLI1) were lower...
BioCentury | Dec 22, 2016
Targets & Mechanisms

Opportunity Knocks

Despite its continued emphasis on tapping external innovation for new opportunities, industry is still leaving on the table scores of unexploited drug targets identified at universities, according to an analysis of BioCentury’s BCIQ: BioCentury Online...
BioCentury | Nov 30, 2016
Distillery Therapeutics


INDICATION: Brain cancer Cell culture and mouse studies suggest c-MET inhibitors could help treat pediatric glioblastomas expressing c-MET fusion oncogenes. In human pediatric glioblastoma cell lines, the c-MET inhibitor foretinib inhibited growth with a lower...
BioCentury | Oct 6, 2016
Distillery Therapeutics

Therapeutics: GLI family zinc finger 1 (GLI1)

Cardiovascular disease INDICATION: Atherosclerosis Patient sample and mouse studies suggest inhibiting GLI1 could help treat atherosclerosis associated with chronic kidney disease (CKD). In patient samples of arterial atherosclerotic plaques and calcified tunica media, levels of...
BioCentury | Sep 15, 2016
Targets & Mechanisms

KOR-recting MS

Although the failed Phase II multiple sclerosis trial of Biogen Inc. 's anti-LINGO mAb in June dealt a blow to myelin repair, a slew of compounds acting by different mechanisms lies behind it in clinical...
BioCentury | Aug 8, 2016
Clinical News

SUBA-Itraconazole: Interim Phase IIb data

Interim data from 13 patients with BCC nevus syndrome (Gorlin Syndrome) in the open-label, U.S. Phase IIb SCORING trial showed that twice-daily 150 mg oral SUBA-Itraconazole for >=16 weeks reduced target tumor burden by >30%...
Items per page:
1 - 10 of 64